Hepatitis C
📧 Sign up to get email alerts when something new happens for Hepatitis C.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2017-11-17Clinical Trial Update: Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection [Phase 2]
Phase 2 clinical trial update evaluating oral regimens for chronic hepatitis C showed efficacy and safety results.
-
CLINICAL_TRIALS trial_result · 2017-11-14Clinical Trial Update: Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis [Phase 3]
Phase 3 trial evaluating eight weeks of SOF/VEL/VOX fixed-dose combination or twelve weeks of SOF/VEL in adults with chronic genotype 3 hepa…
-
CLINICAL_TRIALS trial_result · 2017-11-14Clinical Trial Update: Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects. [Phase 1]
Phase 1 trial evaluating potential drug interaction between eltrombopag and lopinavir/ritonavir in healthy adult subjects. The study status …
-
CLINICAL_TRIALS trial_result · 2017-11-14Clinical Trial Update: Benefit of DAA Therapy in HCV Monoinfected and HIV-HCV Coinfected Patients With Mixed Cryoglobulinemia
This clinical trial update evaluates the benefit of direct-acting antiviral therapy in patients with chronic hepatitis C, including HIV coin…
-
CLINICAL_TRIALS trial_result · 2017-11-13Clinical Trial Update: Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083) [Phase 2]
Phase 2 trial assessing Elbasvir/Grazoprevir with and without Sofosbuvir and Ribavirin in cirrhotic Hepatitis C Genotype 3 patients; complet…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2017-11-09FDA Approved: SOVALDI — Supplemental Application (Gilead Sciences, Inc.)
FDA approved a supplemental application for Sovaldi (sofosbuvir) submitted by Gilead Sciences, Inc., expanding its approved use.
-
FDA approval · 2017-11-09FDA Approved: LEDIPASVIR AND SOFOSBUVIR — Supplemental Application (Asegua Therapeutics LLC)
The FDA approved a supplemental application for ledipasvir/sofosbuvir from Asegua Therapeutics LLC.
-
FDA approval · 2017-11-09FDA Approved: EPCLUSA — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for Epclusa (velpatasvir/sofosbuvir) from Gilead Sciences, expanding its approved uses for hepat…
-
FDA approval · 2017-11-09FDA Approved: VOSEVI — Supplemental Application (Gilead Sciences, Inc.)
FDA approved a supplemental application for VOSEVI (sofosbuvir, velpatasvir, voxilaprevir) from Gilead Sciences, Inc.
-
CLINICAL_TRIALS trial_result · 2017-11-09Clinical Trial Update: Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease [Phase 3]
This completed Phase 3 trial tested an all-oral regimen of Ombitasvir/Paritaprevir/ritonavir with Dasabuvir, with or without Ribavirin, in a…
-
CLINICAL_TRIALS withdrawal · 2017-11-09Clinical Trial Update: Efficacy and Safety of Elbasvir/Grazoprevir in Brazilian Participants With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection With Advanced Fibrosis (F3 and F4) [Phase 4]
A Phase 4 study evaluating elbasvir/grazoprevir in Brazilian participants with chronic HCV genotype 1 and advanced fibrosis was withdrawn.
-
CLINICAL_TRIALS trial_result · 2017-11-08Clinical Trial Update: Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy [Phase 3]
Phase 3 trial assessing safety and efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in adults with chronic hepatit…
-
CLINICAL_TRIALS trial_result · 2017-11-08Clinical Trial Update: First in Human Study of AL-704; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C [Phase 1]
First-in-human study of AL-704 includes single-dose food-effect in healthy volunteers and multiple-dose exposure in chronic hepatitis C; the…
-
CLINICAL_TRIALS trial_result · 2017-11-07Clinical Trial Update: A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients [Phase 2]
Phase 2 study evaluating hepatitis C infection in adult transplant recipients has completed, and results have been posted by AbbVie.
-
CLINICAL_TRIALS research · 2017-11-07Clinical Trial Update: Risk Assessment of Long-Haul Truck Drivers
This clinical trial update reports a completed study assessing risk factors among long-haul truck drivers across several infectious and meta…
-
CLINICAL_TRIALS trial_result · 2017-11-06Clinical Trial Update: Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor [Phase 3]
Phase 3 clinical trial evaluating 12-week regimens of SOF/VEL/VOX fixed-dose combination and SOF/VEL in adults with chronic hepatitis C who …
-
CLINICAL_TRIALS trial_result · 2017-11-06Clinical Trial Update: A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study [Phase 3]
This update reports long-term follow-up data from AbbVie’s hepatitis C trial participants, comparing outcomes based on whether they achieved…
-
CLINICAL_TRIALS trial_result · 2017-11-01Clinical Trial Update: Long-Term Extension Study of Miravirsen Among Participants With Genotype 1 Chronic Hepatitis C (CHC) Who Have Not Responded to Pegylated-Interferon Alpha Plus Ribavirin
A long-term extension study of Miravirsen in genotype 1 chronic hepatitis C patients who did not respond to pegylated interferon alfa plus r…
-
CLINICAL_TRIALS trial_result · 2017-10-31Clinical Trial Update: First in Human Study of ALS-002200; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1 [Phase 1]
This trial update reports the first-in-human study of ALS-002200, including single-dose and food-effect evaluation in healthy volunteers and…
-
CLINICAL_TRIALS trial_result · 2017-10-31Clinical Trial Update: First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1 [Phase 1]
First-in-human study of ALS-002158 evaluated single-dose and food-effect in healthy volunteers and multiple-dose exposure in chronic hepatit…
-
CLINICAL_TRIALS trial_result · 2017-10-27Clinical Trial Update: ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection [Phase 3]
Phase 3 trial assessing AbbVie regimens ABT-450/r/ABT-267 with ABT-333 in treatment-naïve and treatment-experienced adults with chronic hepa…
-
CLINICAL_TRIALS trial_result · 2017-10-27Clinical Trial Update: FibroScan in Patients With Hepatitis B and C Presenting for Liver Biopsy [NA]
Clinical trial evaluating FibroScan in patients with cirrhosis, hepatitis B, or hepatitis C undergoing liver biopsy has completed and posted…
-
CLINICAL_TRIALS withdrawal · 2017-10-25Clinical Trial Update: A First in Human Study of AL-611 in Healthy Volunteers and Patients With Hepatitis C Virus Infection [Phase 1]
A first-in-human Phase 1 study of AL-611 in healthy volunteers and patients with Hepatitis C has been terminated.
-
CLINICAL_TRIALS trial_result · 2017-10-24Clinical Trial Update: Impact of Sofosbuvir and Daclatasvir Concentration on HCV RNA
This completed clinical trial assesses how varying concentrations of Sofosbuvir and Daclatasvir influence Hepatitis C RNA levels.
-
CLINICAL_TRIALS trial_result · 2017-10-24Clinical Trial Update: Phase I-II Vaccination of Autologous Dendritic Cells Transduced With Adenoviral Vector Encoding NS3 in Hepatitis C Encoding NS3 in Hepatitis C [Phase 1, Phase 2]
A Phase I/II trial evaluating an autologous dendritic cell vaccine transduced with an adenoviral NS3 vector for chronic hepatitis C was term…